TECHNOLOGY SUMMARY

IV cNP8 utilizes a peptide (cNP8) engineered to speed healing, minimize scarring, and reduce pain in acute burn wounds. cNP8 can be injected IV at 0.001-0.03mg/kg into the patient at 12-48 hours post-burn. cNP8 can be used to treat burns in prolonged casualty care (PCC) scenarios

AREA/MATURITY/AWARDS

Primary Application Area: Biotech & Medical

Technology Development Status: Proven Manufacturability

Technology Readiness Level: TRL 5

Vetted Programs/Awards: Congressionally Directed Medical Research Programs (CDMRP), Joint Warfighter Medical Research Program (JWMRP), Defense Medical Research and Development Program (DMRDP), Military Burn Research Program (MBRP)

SHOWCASE SUMMARY

Organization Type: Startup Technology Company

Website: https://www.neomatrixtx.com/

MARKET KEYWORDS

Market Keywords: Burns, prolonged casualty care (PCC), intravenous therapy